Detalles de la búsqueda
1.
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
PLoS Med
; 13(10): e1002139, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27727279
2.
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
JCI Insight
; 3(19)2018 10 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30282826
3.
Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Trials
; 16: 86, 2015 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25881192
Resultados
1 -
3
de 3
1
Próxima >
>>